LOS ANGELES, CA / ACCESSWIRE / September 7, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. ("Zogenix" or "the Company") (NASDAQ:ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's shares between February 6, 2019 and April 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before June 11, 2019.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zogenix submitted a New Drug Application to the FDA for FINTEPLA which contained insufficient non-clinical data and furthermore included an incorrect clinical dataset. Based on these errors, the Company was unlikely to gain FDA approval for FINTEPLA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Zogenix, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm
View source version on accesswire.com: